Lipocine's LPCN 2101 Accepted for Presentation at AES 2025 Conference in Atlanta Lipocine Inc. is set to present two significant abstracts on LPCN 2101 at the AES annual meeting in December 2025, focusing on epilepsy treatment.

Lipocine's LPCN 2101 Accepted for Presentation at AES 2025 Conference in Atlanta #United_States #Atlanta #Lipocine #Epilepsy_Treatment #LPCN_2101